Adjuvant Nivolumab Promising in Resected Merkel Cell Carcinoma

(MedPage Today) -- Credit: Klaus D. Peter, Wiehl, Germany Adjuvant therapy with nivolumab (Opdivo) was feasible and safe and appeared to prolong disease-free survival (DFS) in patients with completely resected Merkel cell carcinoma (MCC)...
Source: MedPage Today Dermatology - Category: Dermatology Source Type: news